In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 8, 2014, Pages 1062-1076

  Singh, Gurinder ^a   Pai, Roopa S ^a  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

bioavailability; central composite design; enterohepatic recirculation; in situ single pass intestinal perfusion; in vivo biodistribution

Indexed keywords

EUDRAGIT; NANOPARTICLE; RESVERATROL; ACRYLIC ACID RESIN; DRUG; DRUG CARRIER; EUDRAGIT RS; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; EMULSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RAT; SURFACE PROPERTY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; VALIDATION PROCESS; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PERMEABILITY; PROCEDURES; SOLUBILITY; WISTAR RAT;

ACRYLIC RESINS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; INTESTINAL ABSORPTION; MALE; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; RATS; RATS, WISTAR; SOLUBILITY; STILBENES;

EID: 84904159102     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12232     Document Type: Article

References (52)

1. Bawarski WE, etal. Emerging nanopharmaceuticals. Nanomedicine 2008; 4: 273-282.
2. Li SD, Huang L,. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008; 5: 496-504.
3. Date AA, etal. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine 2010; 5: 1595-1616.
4. Porter CJ, Charman WN,. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001; 50: 61-80.
5. Das S, etal. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces 2011; 88: 483-489.
6. Singh B, etal. Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol. Colloids Surf B Biointerfaces 2013; 101: 465-474.
7. Kumaria A, etal. Development of biodegradable nanoparticles for delivery of quercetin. Colloids Surf B Biointerfaces 2010; 80: 184-192.
8. Singh G, etal. Response surface methodology and process optimization of sustained release pellets using Taguchi orthogonal array design and central composite design. J Adv Pharm Tech Res 2012; 3: 30-40.
9. Singh B, etal. Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert Opin Drug Deliv 2011; 8: 1341-1360.
10. Singh G, etal. Optimization of pellets containing solid dispersion prepared by extrusion/spheronization using central composite design and desirability function. J Young Pharmacists 2012; 4: 146-156.
11. Beloqui A, etal. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release 2013; 166: 115-123.
12. Lopez-Nicolas JM, etal. Determination of stoichiometric coefficients and apparent formation constants for β-cyclodextrin complexes of trans-resveratrol using reversed-phase liquid chromatography. J Chromatogr A 2006; 1135: 158-165.
13. Kristl J, etal. Improvement of cellular stress response on resveratrol in liposomes. Eur J Pharm Biopharm 2009; 73: 253-259.
14. Das S, Ng KY,. Quantification of trans-resveratrol in rat plasma by a simple and sensitive High performance liquid Chromatography method and its Application in pre-clinical study. J Liq Chromatogr Relat Technol 2011; 34: 1399-1414.
15. Amri A, etal. Administration of resveratrol: what formulation solutions to bioavailability limitations. J Control Release 2012; 158: 182-193.
16. Hung CF, etal. Development and evaluation of emulsion-liposome blends for resveratrol delivery. J Nanosci Nanotechnol 2006; 6: 2950-2958.
17. Wegiel LA, etal. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-Impact of different polymers. J Pharm Sci 2013; 102: 171-184.
18. Troche-Pesqueira E, etal. A β-cyclodextrin-resveratrol inclusion complex and the role of geometrical and electronic effects on its electronic induced circular dichroism. RSC Adv 2013; 3: 10242-10250.
19. Nam JB, etal. Stabilization of resveratrol immobilized in monodisperse cyano-functionalized porous polymeric microspheres. Polymer 2005; 46: 8956-8963.
20. Baba K, etal. A method for enhancing the ocular penetration of eye drops using nanoparticles of hydrolysable dye. J Control Release 2011; 153: 278-287.
21. Sanchez-Martnez M, etal. Radiolabeling and biodistribution studies of polymeric nanoparticles as adjuvants for ocular vaccination against brucellosis. Rev Esp Med Nucl Imagen Mol 2013; 32: 92-97.
22. Pongpaibul Y, etal. Preparation and evaluation of controlled release indomethacin microspheres. Drug Dev Ind Pharm 1984; 10: 1597-1616.
23. Ghambarian M, etal. Taguchi OA16 orthogonal array design for the optimization of cloud point extraction for selenium determination in environmental and biological samples by tungsten-modified tube electrothermal atomic absorption spectrometry. Talanta 2009; 78: 970-976.
24. Quevedo MA, etal. P-glycoprotein limits the absorption of the anti-HIV drug zidovudine through rat intestinal segments. Eur J Pharm Sci 2011; 43: 151-159.
25. Kim S, etal. Preparation and physicochemical characterization of trans-resveratrol nanoparticles by temperature-controlled antisolvent precipitation. J Food Eng 2012; 108: 37-42.
26. Singh G, etal. In vivo pharmacokinetic applicability of a simple and validated HPLC method for orally administered trans-resveratrol loaded polymeric nanoparticles to rats. J Pharm Invest 2014; 44: 69-78.
27. Singh G, etal. Development and validation of a HPLC method for the determination of trans-resveratrol in spiked human plasma. J Adv Pharm Tech Res 2012; 3: 130-135.
28. Lu Y, etal. In vitro-in vivo correlation: perspectives on model development. Int J Pharm 2011; 418: 142-148.
29. Dokoumetzidis A, Macheras P,. IVIVC of controlled release formulations: Physiological-dynamical reasons for their failure. J Control Release 2008; 129: 76-78.
30. Ho YF, etal. Application of rat in situ single-pass intestinal perfusion in the evaluation of presystemic extraction of indinavir under different perfusion rates. J Formos Med Assoc 2008; 107: 37-45.
31. Q1A(R2). Stability testing of new drug substances and products, 2003.
32. USP, USP 34, NF 29. The United States Pharmacopeia and The National Formulary. Rockville, MD: The United States Pharmacopeial Convention; 20852, 2011.
33. Mathot F, etal. Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J Control Release 2006; 111: 47-55.
34. Fagerholm U, etal. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996; 13: 1336-1342.
35. Devarajan PV, Sonavane GS,. Preparation and In vitro/In vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carrier. Drug Dev Ind Pharm 2007; 33: 101-111.
36. Oganesyan EA, etal. Use of nanoparticles to increase the systemic bioavailability of trans-resveratrol. Pharm Chem J 2010; 44: 74-76.
37. Almeida L, etal. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy Volunteers. Mol Nutr Food Res 2009; 53: S7-S15.
38. Walle T,. Bioavailability of resveratrol. Ann N Y Acad Sci 2011; 1215: 9-15.
39. Marier JF, etal. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002; 302: 369-373.
40. Lee E, etal. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 2008; 51: 6442-6449.
41. Zhao L, etal. Enhancement of Oral Bioavailability of Puerarin by Polybutylcyanoacrylate Nanoparticles. J Nanomater 2011. doi: 10.1155/2011/126562; Article ID 126562, 8 pages.
42. Planas JM, etal. Resveratrol: A polyphenol with multiple effects. RAPSR 2011; 101-120.
43. Razavi A, Nanodiamond enhanced drugs. US Patent no. 0129457 A1, 2010.
44. Mc Carthy SP, etal. Polysaccharide-containing block copolmer particles and uses thereof. US Patent no. 0020227 A1, 2011.
45. Zhanga J, etal. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int J Pharm 2011; 420: 180-188.
46. Lai SK, etal. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009; 61: 158-171.
47. Gratton SE, etal. Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles. J Control Release 2007; 121: 10-18.
48. Jiao Y, etal. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002; 105: 230-235.
49. Ensign LM, etal. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012; 64: 557-570.
50. Norris DA, etal. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 1998; 34: 135-154.
51. Gao F, etal. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Control Release 2011; 149: 168-174.
52. Jeong EJ, etal. In situ single-pass perfused rat intestinal model for absorption and metabolism. In:, Yan Z, Caldwell GW, eds. Optimization in Drug Discovery. New Jersey: Methods in Pharmacology and Toxicology, 2004: 65-76.